A Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-group Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of XH-S004 Tablets in Patients With Non-cystic Fibrosis Bronchiectasis

Conditions

• Non-Cystic Fibrosis Bronchiectasis

Interventions

• OTHER: XH-S004 20 mg
• OTHER: XH-S004 40 mg
• OTHER: Placebo

Sponsor

S-INFINITY Pharmaceuticals Co., Ltd